Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05002543 · ClinicalTrials.gov registry record
CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting
A clinical trial of Cardiac Valve Disease, sponsored by Corcym S.r.l.
- Recruiting
- Registry status
- 2,150
- Enrollment target
- 20
- Study locations
NCT05002543 is a study of Cardiac Valve Disease that is actively recruiting participants, run by Corcym S.r.l. The registered enrollment target is 2,150 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT05002543, a study of Cardiac Valve Disease, is actively recruiting participants, sponsored by Corcym S.r.l.
- RECRUITING
- Registry status
- 2,150 participants
- Enrollment target
- 20
- Study locations
Study Summary
MANTRA is a prospective, multiple-arm, multi-center, global, post-market clinical follow-up study. The main objective is to monitor ongoing safety and performance of the CORCYM devices and accessories used for aortic, mitral and tricuspid valvular diseases in a real-world setting. Corcym S.r.l., is a medical device manufacturer with a broad product portfolio for cardiac surgeons, offering solutions for the treatment of aortic, mitral and tricuspid valve disease. The MANTRA Master Plan (Master Protocol) is intended as an overarching Umbrella Protocol that allows multiple sub-studies to be added, as needed. The Umbrella Master Protocol concept offers an excellent solution to provide post-marketing clinical follow-up information on the entire cardiac surgery heart valve portfolio of the sponsor in a common database, including corelab assessment of hemodynamic and structural performance, annular motion and Dynamics for one of the products. Currently, three sub-studies are planned: * MANTRA - Aortic Sub-Study * MANTRA - Mitral/Tricuspid Sub-Study (Excluding Memo 4D) * MANTRA - Memo 4D Sub-Study
Conditions Studied
Study Locations (20)
Other
- Innsbruck Medical University - Innsbruck
- Ziekenhuis Oost Limburg - Genk
- UZ Gent - Ghent
- UZ Leuven - Leuven
- University of Calgary (Foothills Hospital) - Calgary
- Hospital Laval IUCPQ - Québec
- St. Michael's Hospital - Toronto
- CHU Clermont-Ferrand_Hopital Gabriel Montpied - Clermont-Ferrand
- Centre Hospitalier de Lens - Lens
- CHU Poitiers - Poitiers
- CHU Toulouse_Rangueil University Hospital - Toulouse
North Carolina
- Duke University - Durham
- East Carolina University - Greenville
Ohio
- University Hospitals Cleveland - Cleveland
- Cleveland Clinic - Cleveland
Pennsylvania
- University of Pennsylvania - Philadelphia
- Lankenau Institute for Medical Research - Wynnewood
Indiana
- St. Vincent Heart Center of Indiana - Indianapolis
Louisiana
- Ochsner Clinic Foundation - New Orleans
Maine
- Maine Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,150 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2035-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05002543
The ClinicalTrials.gov registry entry for NCT05002543 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcym S.r.l, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiac Valve Disease appearing as the primary indexed condition, and to 0 interventions.
NCT05002543 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT05002543 about?
NCT05002543 is a clinical study titled "CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting". MANTRA is a prospective, multiple-arm, multi-center, global, post-market clinical follow-up study. The main objective is to monitor ongoing safety and performance of the CORCYM devices and accessories used for aortic, mitral and tricuspid valvular diseases in a real-world setting. Corcym S.r.l., is...
What is the current status of trial NCT05002543?
This trial is currently recruiting. The enrollment target is 2,150 participants. The study started on 2021-06-29. Estimated completion is 2035-12-31.
What conditions does trial NCT05002543 study?
This clinical trial studies the following conditions: Cardiac Valve Disease.
Who is sponsoring clinical trial NCT05002543?
This trial is sponsored by Corcym S.r.l, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05002543 being conducted?
This trial has 20 study locations across Indiana, Louisiana, Maine, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.